Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036335 · ClinicalTrials.gov registry record · Phase 3
Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 286
- Enrollment target
NCT00036335 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 286 participants.
The verdict
NCT00036335, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 286 participants
- Enrollment target
Study Summary
The purposes of this study are to determine whether an investigational drug can help patients suffering from major depression with pain symptoms, and gather data on the safety of the investigational drug including any side effects that might be associated with it.
Interventions
- DRUG Duloxetine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2002-03 |
| Est. Completion | 2003-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036335
The ClinicalTrials.gov registry entry for NCT00036335 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Duloxetine Hydrochloride is the first listed.
NCT00036335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00036335 about?
NCT00036335 is a clinical study titled "Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain". The purposes of this study are to determine whether an investigational drug can help patients suffering from major depression with pain symptoms, and gather data on the safety of the investigational drug including any side effects that might be associated with it.
What is the current status of trial NCT00036335?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 286 participants. The study started on 2002-03. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00036335?
The interventions under investigation include: Duloxetine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00036335?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.